Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 35

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 35
---
 Since inception, the Company has sought to maximize shareholder value by licensing and acquiring technologies that have scientific merit and ultimately, meaningful market value after commercialization. We believe great opportunity exists for therapeutic agents developed for CNS indications, including neurodegenerative diseases such as Alzheimer’s and Parkinson’s, as well as certain cancers like glioblastoma and neuroblastoma. Due to the heterogeneity of these diseases, there is a wide spectrum of clinical manifestations and outcomes in patients with these conditions. Therefore, there is a strong need for accurate, minimally invasive biomarkers reflective of pathophysiological processes underlying these diseases that can be used for disease progression and treatment response monitoring. As such, the Company’s management finds great value in DiamiR’s innovation and proprietary technology. DiamiR’s platform technology, which is based on targeted selection and quantitative analysis of organ -enriched, including brain -enriched, microRNA (miRNAs) detectable in blood plasma, has a strong potential to provide molecular diagnostic solutions for risk assessment and monitoring of neuro and other indications in clinical trials, which we believe will enable more effective drug development for these indications. DiamiR’s CLIA/CAP -certifiedlab offers and is planning to offer additional genetic and protein markers used in clinical trials for. For example, DiamiR’s validated APOE 4 genotyping test (APOE e4 allele is an established risk factor of AD, while APOE e2 is considered to be neuroprotective) can be used as a screening tool for enrollment into clinical trials targeting APOE e4 carriers or non -carriers. The Company is aware of a need in such test first -handas it holds a position in a private life sciences company Alzheon that is developing a therapeutic agent for AD patients who are APOE e4 carriers. The Company’s private investment position in Alzheon, which consists of 622,600shares of Alzheon’s preferred stock, may create synergies for the post -mergercombined company to potentially provide a diagnostic tool consisting of APOE genotype and miRNA panel testing for their therapeutic offering. Further, DiamiR’s technology and biomarker panels can facilitate identification of new indications for repurposed drugs, such as SACT -1in our pipeline, an agent with previously unrecognized kinase inhibitory activity against MEK5/ERK5 signaling pathway that has shown promise in neuroblastoma. As described below, while building Aptorum’s pipeline via acquisitions